- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03861741
A Study to Evaluate the Feasibility of Screening Relatives of Patients Affected by Non-Syndromic Thoracic Aortic Diseases (ReST)
A Study to Evaluate the Feasibility of Screening Relatives of Patients Affected by Non-Syndromic Thoracic Aortic Diseases: The ReST Study
Study Overview
Status
Intervention / Treatment
Detailed Description
Diseases involving the thoracic aorta (the major artery in the body) are a major health problem affecting an increasing number of people worldwide.
In particular, a group of these conditions termed Non-Syndromic Aortic Diseases (NS-TAD), can develop without any obvious symptoms or external features which prevents early identification. Unfortunately, if not treated, the aorta may enlarge and lead to dissection, a life-threatening medical emergency. For this reason, the investigators believe it might be helpful to investigate relatives of patients undergoing surgery for thoracic aortic disease to understand if there are tests that could help identify and treat this condition at the right time.
Therefore the investigators propose to conduct a feasibility study to identify the practical issues and challenges that would need to be overcome in order to perform a successful tailored genetic (by collecting a small blood sample) and imaging (with exams such as echocardiography and MRI) screening in such population of individuals.
Moreover, all participants will receive two questionnaires to ask their opinion about the study and to measure their levels of anxiety and depression, to judge whether and how this study has affected their emotional status.
The study will be carried out at the Department of Cardiovascular Sciences Glenfield Hospital, University Hospitals of Leicester NHS Trust.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Leicestershire
-
Leicester, Leicestershire, United Kingdom, LE3 9QP
- Department of Cardiovascular Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- NS-TAD probands operated on (n=16).
FDR and SDR, aged 16 and above:
- At least two relatives willing to participate in the screening programme.
- Relatives able to understand English.
Exclusion Criteria:
- Probands with syndromic aortopathies, including Marfan Syndrome, Loeys-Dietz Syndrome, Ehlers-Danlos Syndrome, Shprintzen-Goldberg syndrome, aneurysm-osteoarthritis syndrome, arterial tortuosity syndrome, and cutis laxa syndrome.
- Probands with aortic lesions associated with trauma and infections.
- Probands/relatives unable to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Participants
All participants will be screened through complete clinical evaluations, genetic tests and imaging modalities (TTE and MRI) for the presence of newly Non Syndromic-Thoracic Aortic Diseases.
Demographic and clinical data from all participants will be collected using case report forms, and by accessing their medical records.
Data on imaging investigations will be obtained from TTE and MRI.
Blood samples will be used for the purpose of isolation of genetic material and subsequent whole exome sequencing along with the analysis of selected loci.
Additional citrated blood samples and plasma will be collected and stored for the potential analysis of circulating microvesicles and miRNA.
|
A peripheral venous blood sample will be processed internally, and externally subjected to WES.
Only genetic material from relatives of probands in which a mutation has been identified will be sequenced.
Other Names:
A MRI of the thoracic aorta will be performed in all relatives able to attend the Glenfield Hospital and who have no contra-indications to this imaging modality; pulse-wave velocity will be recorded.
Other Names:
TTE screening will be performed by a trained physiologist.
Aortic diameter will be measured from the parasternal long-axis view at the sinuses of Valsalva and at the widest level of the ascending aorta.
All measurements will be made in end-diastole.
Other Names:
Acceptability questionnaires will be submitted to assess a baseline score of depression/anxiety that will be compared with a follow up value at three months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of genetic diagnosis
Time Frame: Through study completion, an average of 1 year
|
Frequency of first and second degree relatives with newly identified genetic loci associated with NS-TADs.
|
Through study completion, an average of 1 year
|
Rate of diagnosis through imaging modalities
Time Frame: At the end of recruitment stage, an average of 6 months
|
Frequency of newly diagnosed TAD through imaging modalities in first- and second-degree relatives of probands affected by NS-TADs.
|
At the end of recruitment stage, an average of 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Genetic variants
Time Frame: Through study completion, an average of 1 year
|
Genetic variants associated with NS-TADs, identified from a panel of 55 loci, and rate of identification of each mutation.
|
Through study completion, an average of 1 year
|
Family rate of genetic carriers
Time Frame: Through study completion, an average of 1 year
|
Rate of genetic carriers in each affected family.
|
Through study completion, an average of 1 year
|
Penetrance
Time Frame: Through study completion, an average of 1 year
|
Genetic penetrance of the NS-TADs (proportion of individuals carrying a particular variant of a gene that are also affected by NS-TAD).
|
Through study completion, an average of 1 year
|
Mode of inheritance
Time Frame: Through study completion, an average of 1 year
|
Pattern of inheritance of the NS-TADs.
|
Through study completion, an average of 1 year
|
Male: female preponderance
Time Frame: Through study completion, an average of 1 year
|
Male: female preponderance of NS-TADs.
|
Through study completion, an average of 1 year
|
Aortic Compliance
Time Frame: Imaging tests completion, an average of 6 months.
|
Measured as an MRI feature of affected and unaffected thoracic aortas.
|
Imaging tests completion, an average of 6 months.
|
Aortic Distensibility
Time Frame: Imaging tests completion, an average of 6 months.
|
Measured as an MRI feature of affected and unaffected thoracic aortas.
|
Imaging tests completion, an average of 6 months.
|
Rates of concomitant external and cardiovascular characteristics
Time Frame: Baseline clinical assessment
|
Rates of concomitant cardiovascular diseases (e.g.
patent ductus arteriosus, cerebrovascular aneurysm) and external physical features (e.g.
pectus excavates, livedo reticularis).
|
Baseline clinical assessment
|
Response rate
Time Frame: Baseline clinical assessment
|
Response rates (recruitment) among the probands and their relatives.
|
Baseline clinical assessment
|
Acceptability questionnaires
Time Frame: Baseline and 3 months follow up
|
Semi-quantitative evaluation of the participant experience awareness and acceptability of the screening and consent process, obtained by questionnaires administered to the patients and relatives. Scales will be composed by 10 items, each can be rated with a score from 1 to 5. No threshold will be preset. Descriptive statistics will be used to present the results. |
Baseline and 3 months follow up
|
Depression evaluation
Time Frame: Baseline and 3 months follow up
|
Semi-quantitative evaluation of the impact of the screening process on depression in probands and their relatives (baseline and 3 months), based on Patient Health Questionnaire (PHQ-9) score.
Score range goes from 0 to 27, proposed cut-off for active treatment is 15.
|
Baseline and 3 months follow up
|
Anxiety evaluation
Time Frame: Baseline and 3 months follow up
|
Semi-quantitative evaluation of the impact of the screening process on anxiety in probands and their relatives (baseline and 3 months), based on Generalized Anxiety Disorder (GAD-7) score.
Score range goes from 0 to 21, proposed cut-off for further assessment is 10.
|
Baseline and 3 months follow up
|
Health-related Quality of Life evaluation
Time Frame: Baseline and 3 months follow up
|
Semi-quantitative evaluation of the impact of the screening process on health-related quality of life in probands and their relatives (baseline and 3 months), based on Short Form (36) Health Survey (SF-36) score.
Said questionnaire is made up of eight scales, which are the weighted sums of the items for each section; a score of zero corresponds to maximum disability while 100 correlates to no disability.
|
Baseline and 3 months follow up
|
Resource use of genetic screening
Time Frame: 3 months follow up
|
Resource uses in terms of unitary costs of the genetic screening process.
|
3 months follow up
|
Resource use of imaging screening
Time Frame: 3 months follow up
|
Resource uses in terms of unitary costs of the imaging screening process.
|
3 months follow up
|
Resource use (hospital visits)
Time Frame: 3 months follow up
|
Number of participants reaching the research centre.
|
3 months follow up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Giovanni Mariscalco, Prof, University of Leicester
Publications and helpful links
General Publications
- Mariscalco G, Debiec R, Elefteriades JA, Samani NJ, Murphy GJ. Systematic Review of Studies That Have Evaluated Screening Tests in Relatives of Patients Affected by Nonsyndromic Thoracic Aortic Disease. J Am Heart Assoc. 2018 Aug 7;7(15):e009302. doi: 10.1161/JAHA.118.009302.
- Abbasciano RG, Mariscalco G, Barwell J, Owens G, Zakkar M, Joel-David L, Pathak S, Adebayo A, Shannon N, Haines RL, Aujla H, Eagle-Hemming B, Kumar T, Lai F, Wozniak M, Murphy G. Evaluating the Feasibility of Screening Relatives of Patients Affected by Nonsyndromic Thoracic Aortic Diseases: The REST Study. J Am Heart Assoc. 2022 Apr 19;11(8):e023741. doi: 10.1161/JAHA.121.023741. Epub 2022 Apr 6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0676
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genetic Disease
-
Boston Children's HospitalNational Human Genome Research Institute (NHGRI)Active, not recruitingGenetic Disease | Genetic PredispositionUnited States
-
Boston Children's HospitalRecruitingGenetic Predisposition to Disease | Genetic Disease | Development, Infant | Genetic Syndrome | Development, ChildUnited States
-
National Cancer Institute (NCI)Active, not recruitingCancer | Hereditary Neoplasms | Genetic Predisposition to Cancer | EnvironmentUnited States
-
Anahuac UniversityCompletedGenetic Predisposition | Carrier, GestationalMexico
-
University of WashingtonNational Cancer Institute (NCI)Completed
-
University Hospital TuebingenCharite University, Berlin, Germany; RWTH Aachen University; Medical University...Not yet recruiting
-
King Hussein Cancer CenterActive, not recruiting
-
University of Texas Southwestern Medical CenterNational Society of Genetic CounselorsCompletedGenetic PredispositionUnited States
-
National Cancer Institute (NCI)RecruitingCancer | Hereditary Neoplasms | Genetic Predisposition to Cancer | EnvironmentUnited States
-
Jerry Vockley, MD, PhDEnrolling by invitationGenetic Disease | Infant, Newborn, DiseaseUnited States
Clinical Trials on WES
-
University of California, San FranciscoCompletedSkeletal Anomalies | Multiple Anomalies | Structural Anomalies | Cardiac Anomalies | Central Nervous System Anomalies | Thorax Anomalies | Genito-urinary Anomalies | Gastrointestinal AnomaliesUnited States
-
Second Xiangya Hospital of Central South UniversityShanghai OrigiMed Co., Ltd.RecruitingLung Squamous Cell CarcinomaChina
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedFetal Agenesis of the Corpus Callosum (ACC)France
-
Rady Pediatric Genomics & Systems Medicine InstituteActive, not recruiting
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Stichting MetakidsCompletedInherited Metabolic DisordersNetherlands
-
Regina Elena Cancer InstituteRecruiting
-
Carmel Medical CenterActive, not recruitingMicrobial Colonization | Genetic Predisposition | Health Services AdministrationIsrael
-
Hospices Civils de LyonCompletedAutism Spectrum Disorder | Williams Beuren Syndrome
-
Case Comprehensive Cancer CenterNot yet recruiting